UK markets closed
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • FTSE 250

    22,883.39
    +206.11 (+0.91%)
     
  • AIM

    1,232.54
    +4.45 (+0.36%)
     
  • GBP/EUR

    1.1675
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • BTC-GBP

    24,878.35
    +175.16 (+0.71%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.20 (+0.68%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • HANG SENG

    27,321.98
    -401.86 (-1.45%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • CAC 40

    6,568.82
    +87.23 (+1.35%)
     

Global Single Photon Emission Computed Tomography (SPECT) Market to Reach US$2.7 Billion by the Year 2027

·23-min read

Abstract: - Global Single Photon Emission Computed Tomography (SPECT) Market to Reach US$2. 7 Billion by the Year 2027. - Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.

New York, June 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Single Photon Emission Computed Tomography (SPECT) Industry" - https://www.reportlinker.com/p06097755/?utm_source=GNW
7 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 6.8% over the period 2020-2027.Standalone, one of the segments analyzed in the report, is projected to grow at a 6.2% CAGR to reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybrid segment is readjusted to a revised 7.5% CAGR for the next 7-year period. This segment currently accounts for a 43.8% share of the global Single Photon Emission Computed Tomography (SPECT) market.

- The U.S. Accounts for Over 36.1% of Global Market Size in 2020, While China is Forecast to Grow at a 9.4% CAGR for the Period of 2020-2027

- The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$608.4 Million in the year 2020. The country currently accounts for a 36.07% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$298.9 Million in the year 2027 trailing a CAGR of 9.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5% and 6.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR while Rest of European market (as defined in the study) will reach US$298.9 Million by the year 2027.

- Select Competitors (Total 45 Featured)

  • Bruker Corporation

  • Digirad Corporation

  • Esaote SpA

  • GE Healthcare

  • Invicro, LLC

  • Mediso Medical Imaging Systems

  • MR Solutions Ltd.

  • Philips Healthcare

  • Siemens Healthineers

  • Trifoil Imaging, Inc.




Read the full report: https://www.reportlinker.com/p06097755/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
SPECT in Diagnosing Pulmonary Embolism in COVID-19 Patients
A Prelude to Single-Photon Emission Computed Tomography (SPECT)
Prominent Indications for SPECT Scanning
Global SPECT Market to Witness Steady Growth over the Coming Years
Hybrid SPECT Systems Witness Increased Demand
Cardiology Dominates the Application for SPECT
EXHIBIT 1: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
United States Dominates the Global SPECT Market, Asia-Pacific
to Register Faster Growth
Competition
Recent Market Activity
WORLD BRANDS

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
SPECT Dominates the Nuclear Medicine Market
EXHIBIT 2: Global Radiopharmaceuticals Market Revenues in U$
Million for Years 2019, 2021, 2023, 2024 & 2025
EXHIBIT 3: Worldwide Installed Base of Nuclear Imaging
Equipment by Modality (2019): Percentage Breakdown of Units
Installed for PET and SPECT
SPECT Systems with Anger Camera Remain the Dominant Type
Rapidly Growing Geriatric Population and the Rise in Associated
Diseases Catalyze Growth
EXHIBIT 4: Global Population of 65+ Individuals (In 000s) by
Region for the Years 2015, 2020, 2025, 2030 & 2040
Rising Incidence of Chronic Diseases Propels the Demand for
Medical Imaging
EXHIBIT 5: Global Cost of Chronic Diseases (In US$ Billion) for
the Years 2018 and 2030
Oncology Diagnostic Imaging to Witness Rapid Growth
EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 7: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
Growing Emphasis on Early Diagnosis is a Driving Factor for
Diagnostic Imaging
Rise in Healthcare Expenditure to Drive Growth
EXHIBIT 8: Elderly Healthcare Expenditure as a % of GDP
EXHIBIT 9: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
SPECT Systems with Anger Camera Remain the Dominant Type
Growing Demand for Dual-Modality and Organ-Specific Systems
Augurs Well
Growing Adoption of Hybrid Diagnostic Imaging Modalities
SPECT-CT
Commercialization of SPECT/CT Systems with Enhanced Features
Surges
SPECT Combined with CT and PET, the new Rage
Integration of X-ray CT Enhances SPECT Capabilities
Proper Selection of Isotopes - Highly Important for SPECT
Sustained Opportunities for Ga-67 SPECT Systems
PET Eclipses SPECT in Cardiovascular Imaging
Personalized Medicine Drives SPECT Market
EXHIBIT 10: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population
EXHIBIT 11: Global Personalized Medicine Market: Revenues in
US$ Million for the Years 2019 and 2024
Rise in Incidence of Neurological Disorders to Drive Growth
Technological Advancements in the Recent Past
Yale University Research Team Attempts to use Deep Learning for
Estimating Attenuation Maps using SPECT Emission Data (2020)
Siemens Healthineers Debuts New Version of c.cam Cardiac SPECT
System
NorthStar Medical Radioisotopes Advances Focus on Therapeutic
and Specialized SPECT Radiopharmaceuticals
Technological Advancements in Cardiac SPECT (2019)

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Standalone by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Standalone by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Standalone by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Hybrid by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Hybrid by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Hybrid by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Diagnostic Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Diagnostic Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 31: USA Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 38: USA Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 39: USA 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

CANADA
Table 40: Canada Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 47: Canada Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 48: Canada 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

JAPAN
Table 49: Japan Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: Japan Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 57: Japan 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

CHINA
Table 58: China Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 65: China Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 66: China 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

EUROPE
Table 67: Europe Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 77: Europe Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 78: Europe 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

FRANCE
Table 79: France Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Application - Percentage
Breakdown of Value Sales for Cardiology, Oncology, Neurology
and Other Applications for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 86: France Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 87: France 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Diagnostic Centers and Other
End-Uses for the Years 2012, 2020 & 2027

GERMANY
Table 88: Germany Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Percentage Breakdown of Value Sales for Standalone and Hybrid
for the Years 2012, 2020 & 2027

Table 91: Germany Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Single Photon
Emission Computed Tomography (SPECT) by Application -
Percentage Breakdown of Value Sales for Cardiology, Oncology,
Neurology and Other Applications for the Years 2012, 2020 &
2027

Table 94: Germany Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Hospitals,
Diagnostic Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 95: Germany Historic Review for Single Photon Emission
Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 96: Germany 15-Year Perspective for Single Photon
Emission Computed Tomography (SPECT) by End-Use - Percentage
Breakdown of Value Sales for Hospitals, Diagnostic Centers and
Other End-Uses for the Years 2012, 2020 & 2027

ITALY
Table 97: Italy Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Product Type -
Standalone and Hybrid - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Standalone and
Hybrid Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Single Photon Emission
Computed Tomography (SPECT) by Product Type - Percentage
Breakdown of Value Sales for Standalone and Hybrid for the
Years 2012, 2020 & 2027

Table 100: Italy Current & Future Analysis for Single Photon
Emission Computed Tomography (SPECT) by Application -
Cardiology, Oncology, Neurology and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Single Photon Emission
Computed Tomography (SPECT) by Application - Cardiology,
Oncology, Neurology and Other Applications Mark
Read the full report: https://www.reportlinker.com/p06097755/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting